Epcoritamab and Rituximab for First-line Follicular Lymphoma

This study is testing a combination of epcoritamab (a bispecific antibody that engages immune cells) and rituximab (a standard lymphoma drug) as a first-line treatment for follicular lymphoma — a slow-growing type of non-Hodgkin lymphoma. The goal is to see if this chemotherapy-free combination can effectively treat newly diagnosed follicular lymphoma. **You may be eligible if:** - You have been newly diagnosed with follicular lymphoma (grade 1–3A) confirmed by biopsy, with no prior transformation to aggressive lymphoma - You have not received any prior systemic (drug) treatment for follicular lymphoma - Your disease meets at least one criterion for starting treatment (such as symptomatic lymph nodes, organ impairment, or low blood counts caused by disease) **You may NOT be eligible if:** - You have previously received systemic therapy for follicular lymphoma - Your lymphoma has transformed to a more aggressive subtype - You do not meet the treatment threshold criteria Talk to your doctor to see if this trial is right for you.